Associated Papers
The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers.
De Mattos-Arruda L et al.
Npj Breast Cancer, 2021
34099718 (PubMed )
Supplement: 41523_2021_282_MOESM1_ESM.xlsx › Suppl_Table_1
Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance.
Martin LA et al.
Nature Communications, 2017
29192207 (PubMed )
Supplement: 41467_2017_1864_MOESM3_ESM.xlsx › MCF7-LTEDY537C
Exome sequencing deciphers a germline MET mutation in familial epidermal growth factor receptor-mutant lung cancer.
Tode N et al.
Cancer Science, 2017
28294470 (PubMed )
Supplement: CAS-108-1263-s001.pdf
Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance.
Raaijmakers MI et al.
Oncotarget, 2016
27791198 (PubMed )
Supplement: oncotarget-07-77163-s002.xlsx › Patient_2_late_met_3
Age-related mutations and chronic myelomonocytic leukemia.
Mason CC et al.
Leukemia, 2016
26648538 (PubMed )
Supplement: 41375_2016_BFleu2015337_MOESM120_ESM.xlsx › ST7
Select a paper to view details